Innate Pharma SA
Marty Duvall has extensive experience in the biotechnology and pharmaceutical sectors, currently serving as an Independent Director on the Board of Directors for both Innate Pharma and a private company since January 2024. Duvall previously held the position of Chief Executive Officer and Board of Directors Member at Angiex Inc from June 2022 to December 2023, and served as Chief Executive Officer at Oncopeptides AB from July 2020 to November 2021, as well as at Tocagen from November 2016 to July 2020. Duvall's educational background includes a Master’s degree in Chemistry from The Johns Hopkins University and a Bachelor’s degree in Chemistry from Muhlenberg College.
This person is not in any teams
This person is not in any offices
Innate Pharma SA
2 followers
Innate Pharma SA is a France-based biopharmaceutical Company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The Company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk.